A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan (clinicaltrials.gov) - Oct 16, 2026 - P=N/A | N=1067 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Nov 2026 ➔ May 2027 | Trial primary completion date: Nov 2026 ➔ May 2027
Real-world evidence • Trial completion date • Trial primary completion date • Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer
|